For each citation that was shared on social media (LinkedIn, Facebook, or Twitter) with the “@GenScript” tag, the author will be rewarded with a $10 Amazon gift card or 2,000 GS points.

Development and characterization of anti-IL-5 monoclonal antibody Fab fragment for blocking IL-5/IL-5Rα binding

International Immunopharmacology. 2023-10; 
Shijie Li , Shijie Wang , Eric Fordjour , Yaoji Liang , Xuelian Wang , Yonghao Ye , Zhonghu Bai , Yankun Yang , Yongqi Chen
Products/Services Used Details Operation
Gene Synthesis Gene synthesis and plasmid construction (Supplementary method 3) of 20A12-Fab was performed by GenScript Corporation (China)/An overlapping peptide library was designed and synthesized in Genscript Get A Quote
Peptide Synthesis Get A Quote

Abstract

Interleukin-5 (IL-5) is a homodimeric cytokine that is a crucial regulator of the proliferation, activation, and maturation of eosinophils. Anti-IL-5 monoclonal antibodies, which block the binding of IL-5 to the IL-5 receptor subunit alpha (IL-5Rα), have been successfully used to treat eosinophilic (EOS) asthma. The currently marketed monoclonal antibody drugs require repeated injections for administration, which seriously affect patient compliance and high systemic exposure for injectable drug delivery. Here we successfully screened and developed the Fab (fragment of antigen binding), which is 1/3rd the molecular weight of IgG, favoring inhalationmediated delivery to the lungs, making it more effective for... More

Keywords

Eosinophilic asthma Fab fragment antibody Inhalation-mediated delivery Interleukin-5 Interleukin-5 receptor subunit alpha